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Abstract
An in silico study was carried out to identify antigens for their possible collective use as vaccine candidates against
diseases caused by different classes of pathogenic mycobacteria with significant clinical relevance. The genome
sequences of the relevant causative agents were used in order to search for orthologous genes among them.
Bioinformatics tools permitted us to identify several conserved sequences with 100% identity with no possibility of
cross-reactivity to the normal flora and human proteins. Nine different proteins were characterized using the strain
H37Rv as reference and taking into account their functional category, their in vivo expression and subcellular
location. T and B cell epitopes were identified in the selected sequences. Theoretical prediction of population
coverage was calculated for individual epitopes as well as their combinations. Several identical sequences,
belonging to six proteins containing T and B cell epitopes which are not present in selected microorganisms of
the normal microbial flora or in human proteins were obtained.
Introduction
There are different species of mycobacteria that cause
many human infections with high mortality and morbi-
lity [1,2]. Three of the most common diseases caused by
them are tuberculosis (TB), leprosy and Buruli ulcer.
Atypical mycobacteria are the causative agents of dis-
eases caused by mycobacteria other than M. tuberculosis
(MTB) and M. leprae. Infections with these species have
become more frequent nowadays. HIV infection, socioeco-
nomic conditions and antibiotic resistance are some of the
reasons for the increased prevalence of these diseases [3].
This fact may also be associated with the waning protec-
tive effect of BCG [4].
The absence of an effective vaccine against mycobacter-
ial diseases [5-7] and its high prevalence in poor countries
with low accessibility to health services justified the search
for vaccine candidates that can be used to simultaneously
protect humans against diseases caused by the different
pathogenic mycobacteria [8].
Vaccine design can be expedited via the application of in
silico techniques combined with immunological methods.
Bioinformatics tools enable researchers to move rapidly
from genomic sequence to vaccine design. These new
tools allow the selection of regions of microbial genomes
that are predicted to trigger protective immune responses
to be used as components for vaccine constucts [9,10].
The present research aims to identify antigens using
in silico studies for the development of vaccine candi-
dates that can simultaneously protect humans against
diseases caused by pathogenic mycobacteria.
Materials and methods
The mycobacteria genomes were retrieved from Gene
Bank database (http://www.ncbi.nlm.nih.gov/).
A whole–genome alignment was performed using
Mauve tools in order to search for orthologous genes with
identities ranging from 98 to 100% homology.
A local alignment among all protein sequences for each
orthologous genes was perfomed with Clustalw program,
and all sequences having identity of more than 20 continu-
ous amino acids were chosen.* Correspondence: aracosta2005@yahoo.es
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Selection of similar genetic regions among mycobac-
teria and genetic regions from selected bacterial flora of
the normal microbiome was also performed.
The amino acid sequences obtained were compared with
the available sequences of selected microbiome using the
local alignment tool FASTA 36.3.4. The parameters for
the program were ktup=2, DNA STRAND=N/A and
SEQUENCE= PROTEIN.




Escherichia coli ‘BL21-Gold (DE3)pLysS AG’
Lactobacillus acidophilus NCFM
Mycobacterium smegmatis str. MC2 155
Staphylococcus epidermidis ATCC 12228,
Streptococcus agalactiae 2603V/R
Streptococcus sanguinis SK36.
Finally, sequences below 70% homology and those
without theoretical possibilities of forming linear B cell
epitopes were selected.
Prediction of subcellular localization of proteins
The subcelular localization of the selected proteins was
defined using the report of the identification and locali-
zation of 1044 MTB proteins [11].
Subcelular localization of proteins that did not appear in
the report was predicted using three servers: PSORTb [12],
TBpred, [13] and SignalP [14].
Identification and selection of in-vivo expressed genes
A bibliographic search was performed to look for
reports of in-vivo studies of MTB gene expression in
humans and animals using google scholar, PubMed and
PubMed Central.
HLAPred server was used for prediction of T-cell epitopes
in this study
Thirty six HLA class I and 51 HLA class II were selected
for the prediction. The results were displayed in HTML
Mapping form and the threshold of 3% were use as
default for the prediction parameters [11]. T cell epitopes
similar to human epitopes were eliminated.
B-cell epitope prediction
Two servers, Bcepred and ABCpred, were combined for
the prediction of linear B cell epitomes. For Bcepred ser-
ver: Seven physico-chemical properties of amino acids
(hydrophilicity, flexibility, accessibility, polarity, exposed
surface and turns and antigenic propensity) were com-
bined with a threshold at 2.38. For ABCpred server: A
threshold of 0.5 and the predicted B cell epitope length of
16 amino acids were used [12]. The regions containing
both T and B cell epitopes were selected by BioHelper
tools [15].
The epitopes analyzed were compared with the report
of Iñakis et al. [16] for eliminating hyperconserved
epitopes.
Population coverage calculation of individual epitopes
and their combinations
The theoretical prediction of the presentation of the indi-
vidual epitopes and their combinations for MHC alleles of
Cuban, Malaysian, Brazilian, Mexican, Australian, African,
and North American populations were calculated using
the Population Coverage Calculation program [18].
The percentage of coverage greater than 70% was
accepted as good consistent with reports in the litera-
ture [18,10,19,11,14] (figure 1).
Results
Thirteen-whole mycobacteria genome alignments were
performed and 26 orthologous genes were determined. A
local alignment among each protein sequence for each
orthologous gene was performed and 71 sequences were
obtained with more than 20 identical amino acids between
them, corresponding to 14 proteins.
In order to avoid the selection of epitopes share with
the host microbiome only, only 20 epitopes were
retained in this study. It was found that 13 of 14 pro-
teins were expressed in the membrane; with six only
expressed in the membrane, two in the membrane and
cell wall; three in the membrane and cytosol and two in
all of these compartments. One protein was only
expressed in the cytosol [20,21].
Table 1 shows a characterization of predicted proteins
containing sequences showing 100% identity among
pathogenic mycobacteria, and not shared with human pro-
teins or the normal human microbiome. These proteins
have also been predicted to contain T and/ or B cell
epitopes, and are expressed during infection.
Four of the identified genes (Rv1269, Rv0667, Rv1547
and Rv1384) have been reported to be up-regulated dur-
ing infection. Rv1299 is over-expressed during infection
in human macrophages, mice and guinea pig lungs [22].
Rv0667, Rv1547and Rv1384 are over-expressed only
during infection in guinea pig lungs [23].
The selected sequences from Rv0701, Rv1384 and
Rv1308 are not predicted to contain T cell epitopes but
were chosen based on reports of their potential role in
the humoral immune response against MTB [23-25].
Hyperconserved epitopes are not present in the selected
sequences. These sequences were excluded to avoid
regions, which may be selected during the co-evolution of
MTB and humans and hence may provide an advantage to
the pathogen [17].
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Five sequences that contain epitopes similar to human
epitopes were eliminated [13] to avoid potential autoim-
mune response.
In this research, the identified sequences belonging to 15
MTB proteins and some of its combinations were analyzed.
The combination of all sequences were predicted to give
more than 70% population coverage when presented via
the MHC class I plus MHC class II molecules in the
selected geographical regions. In contrast, the predicted
population coverage of individual sequences was highly
variable in the different geographical regions and was
always bellow 70 % (data not shown). However, these
sequences were not excluded because of their potential use
in the specific geographical regions.
The combination of all sequences shows population
coverage over 70 % in all geographical regions studied
(Figure 2).
Evaluation of the identified sequences in in vitro and
in animal models should be carried out to verify their
utility to be included in vaccine formulations.
Figure 1 Flowchart of the procedure –bioinformatics analysis
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Conclusions
We used bioinformatics tools to predict sequences,
which are common among different mycobacteria
belonging to the MTB complex and are absent from
selected microorganisms of the normal flora. The pre-
dicted sequences comprise those that are expressed pri-
marily in the membrane and contain B and T cell
epitopes that do not match with the human epitopic
database. The combination of the identified sequences
gives appropriated theoretical population coverage in
the different geographic regions studied. These pre-
dicted sequences are potential vaccine candidates but
functional/biological assays should be performed to ver-
ify whether they are indeed appropriate to be included
in a vaccine formulation.
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Table 1 Characterization of predicted proteins
Identification (ORF) T epitopes B epitopes Up-regulation during infection
Rv0667 YES YES YES
Rv1299 YES NO YES
Rv1315 YES YES NO
Rv1420 YES NO NO
Rv1421 YES YES NO
Rv1547 YES YES YES
Rv0701 NO YES NO
Rv1308 NO YES NO
Rv1384 NO YES YES
Figure 2 Population coverage for combination of all sequences
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